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Background. Chikungunya virus (CHIKV) and related arboviruses have been responsible for large epidemic
outbreaks with serious economic and social impact. Although infected individuals clear the virus from the blood,
some develop debilitating and prolonged arthralgia.
Methods. We investigated speciﬁcity and strength of antibody responses in a longitudinal study on
CHIKV-infected patients and analyzed their association with viral load, cytokine proﬁle, and severity.
Results. We found that CHIKV-speciﬁc response is dominated by immunoglobulin G3 (IgG3) antibodies.
The antibodies were neutralizing, and patients with high viremia rapidly developed high levels of anti-CHIKV
antibodies of this speciﬁc isotype. Although these patients endured a more severe disease progression during the
acute viremic phase, they cleared the virusfaster and did not experience persistentarthralgia. However, signiﬁcant
persistent arthralgia was observed in patients with low viremia who developed IgG3 at a later stage.
Conclusions. Absence of early CHIKV-speciﬁc IgG3 may therefore serve as a speciﬁc marker of patients with
increased risk of disease.
In several arthralgia-causing arbovirus outbreaks,
morbidity has been unexpectedly high with extensive
incapacitation, including some lethal cases [1, 2].
Some were caused by chikungunya virus (CHIKV),
ﬁrst isolated in 1953 in Tanzania from infected patients
who often developed a contorted posture caused by
debilitating joint pain [3–5]. The reemergence of
CHIKV since 2005 has caused millions of cases
throughout countries in and around the Indian Ocean
and Southeast Asia [6], and sporadic outbreaks are
still ongoing in several countries, inﬂicting naive pop-
ulations [7]. Singapore, for instance, experienced 2 suc-
cessive waves of chikungunya fever (CHIKF) outbreaks
in January and August 2008 [8–10]. Although there were
only 718 laboratory-conﬁrmed cases reported in 2008
and 341 cases in 2009 [11, 12], CHIKF remains a public
threat due to the low herd immunity. Therefore, it may
represent a major public health problem with severe
social and economic impact.
CHIKV is a mosquito-borne virus belonging to the
Alphavirus genus of the Togaviridae family. It has a life
cycle similar to other alphaviruses and causes sudden
onset of fever, rashes, arthritis, and other accompa-
nying symptoms [3, 4]. Following the acute phase of
the illness, patients develop severe chronic symptoms
lasting from several weeks to months, including fati-
gue, incapacitating joint pain, and polyarthritis [13, 14].
However, as in many other arthralgia-causing
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af r a c t i o no fp a t i e n t s[ 1–5]. A role for both innate and
adaptive immunity has been proposed [15], but the mecha-
nisms underlying control of viral replication and dissemination,
viral clearance, and acute and chronic disease severity remain
poorly deﬁned.
In the current study, we analyzed the timing, speciﬁcity, and
isotype of the antibody response against CHIKV by longitudinally
analysis of 30 patients who were hospitalized for acute CHIKF [9,
10]. By correlating the antibody response with viral load, cytokine
proﬁle, and disease progression during the acute and the chronic
phases, we show that neutralizing immunoglobulin G3 (IgG3)
antibodies clearly dominate the response. Notably, the early in-
duction of anti-CHIKV IgG3 antibodies is strongly associated
with protection against persistent arthralgia, whereas a delayed
response in patients with low viremia correlates with chronic joint
pain. Thus, a strong virus-speciﬁc antibody response induced by
high virus titers in the viremic phase seems to promote full pro-
tection against severity at the later stages of the disease.
MATERIALS AND METHODS
Ethical Approval
Written informed consent was obtained from all partic-
ipants. This study was approved by the National Health-
care Group’s Domain-Speciﬁc Ethics Review Board (DSRB
Reference No. B/08/026).
Patients and Plasma Collection
Thirty patients admitted with acute CHIKF to the Com-
municable Disease Centre at Tan Tock Seng Hospital during
the outbreak from 1 August to 23 September 2008 [9, 10]
were included in this study. Plasma specimens were collected
at 4 time points post–illness onset (PIO): (1) acute phase
(median, 4 days PIO); (2) early convalescent phase (median,
10 days PIO); (3) late convalescent phase (4–6 weeks PIO);
and (4) chronic phase (2–3 months PIO). Clinical features
deﬁnition and clinical samples were as described previously
[9, 10]. Illness was deﬁned as severe if a patient had a maxi-
mum temperature .38.5C, a maximum pulse rate .100
beats per minute, or a nadir platelet count ,100 3 10
9/L.
A r t h r a l g i aw a sd e ﬁ n e da sh a v i n gp a i ni n.1 joints, with or
without joint inﬂammation. Patients were later clustered
into early and late IgG3 responders based on their IgG3 titer
measured at a median of 10 days PIO (Table 1).
Immunologic Analyses
Antibody titers were assessed by a virion-based enzyme-
linked immunosorbent assay (ELISA). Polystyrene 96-well
microtiter plates (Ma x i S o r p ,N u n c )w e r ec o a t e dw i t hp u r i ﬁ e d
CHIKV (20 000 virions/lL in phosphate-buffered saline [PBS];
50 lL per well). Wells were blocked with PBS containing
0.05% Tween-20 and 5% nonfat milk (Phosphate buffered
saline Tween 20 [PBST]-milk), and plates were incubated for
1.5 hours at 37C. Plasma samples were then diluted 1:100 to
1:2000 in PBST-milk and incubated for 1 hour at 37C.
Horseradish peroxidase–conjugated mouse antihuman im-
munoglobulin G (IgG), immunoglobulin G1 (IgG1), im-
munoglobulinG2 (IgG2), IgG3, immunoglobulinG4 (IgG4),
and immunoglobulin M (IgM) (Molecular Probes) were used
to detect human antibodies bound to virus-coated wells.
Reactions were developed using 3,3#,5,5#-Tetramethylbenzidine
(TMB) substrate (Sigma-Aldrich) and terminated by Stop
reagent (Sigma-Aldrich). Absorbance was measured at
450 nm. Healthy donor samples were used as controls. ELISA
readings were done in duplicates. Antigenic responses were
detected by immunoﬂuorescence assay as described. HEK
293T cells were seeded on coverslips coated with human plasma
ﬁbronectin (Sigma-Aldrich). Virus infection was performed at
a multiplicity of infection (MOI) of 10. At 6 hours post-
infection, cells were ﬁxed with PBS containing 4% para-
formaldehyde. Cells were then permeabilized in PBS containing
0.2% Triton-X and blocked with PBS supplied with 10% fetal
bovine serum (FBS). Cells were stained with patients’ plasma
diluted in PBS (1:500) containing 1% bovine serum albumin
for 1 hour at 37C. This was followed by incubation with
goat antihuman secondary antibody conjugated to Alexa
F l u o r4 8 8( M o l e c u l a rP r o b e s )f o r1h o u ra t3 7 C. Cells were
washed, mounted, and examined with a confocal laser-
scanning microscope (Fluoview FV100; Olympus) using 203
numerical aperture (NA) 0.75 or 603 NA 1.42 objective.
Images were collected using FV10-ASW software and processed
with Adobe Photoshop software. Levels of cytokines were mea-
sured by multiplex bead–based arrays as described previously
[16].
Seroneutralization
Neutralizing activity of antibodies from CHIKV-infected
patient samples were tested in triplicates and analyzed by
immunoﬂuorescence-based cell infection assay in HEK 293T cells.
Chikungunya virus was mixed at a MOI of 10 with diluted (1:100,
500, or 1000), heat-inactivated human plasma and incubated for
2h o u r sa t3 7 C with gentle agitation (350 rpm). Virus-antibody
mixtures were then added to HEK 293T cells seeded in 96-well
plates and incubated for 1.5 hours at 37C. Medium was removed,
and cells were replenished with Dulbecco’s modiﬁed Eagle’s
medium supplied with 5% FBS and incubated for 6 hours at
37C before ﬁxation with 4% paraformaldehyde, followed by
immunoﬂuorescence quantiﬁcation using the Cellomics Array-
Scan V. Percentage of infectivity was calculated according to the
equation [% infectivity 5 100 3 (% responder from seroneu-
tralization group/% responder from virus infection group)].
Affinity Depletion of Anti-CHIKV Antibodies
For afﬁnity depletion of human anti-CHIKV antibodies,
puriﬁed Chikungunya virions (1 3 10
6 virions per well) were
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24 hours in PBS. Human plasma samples were added and
incubated for 25 minutes at room temperature for absorp-
tion. The unbound portion was collected after 21 rounds of
absorption. ELISA analysis was performed to verify the levels
of the antibodies during afﬁnity depletion.
Affinity Depletion of Human Isotype IgG3 Antibodies
For afﬁnity depletion of human isotype IgG3 antibodies,
mouse biotinylated monoclonal antihuman IgG3 antibodies
(30 lg/mL, Molecular Probes) were added to Immobilizer
Streptavidin plates (Nunc) and incubated at room temperature
for1hourinPBS containing 0.02% Tween-20 (0.02% PBST).
Human plasma samples were added and incubated for
25 minutes at room temperature for absorption. The un-
bound portion was collected after 21 rounds of absorption.
ELISA analysis was performed to verify the levels of the anti-
bodies during afﬁnity depletion.
Data Analysis
Data are presented as mean 6 standard error of the mean
(SEM) or as mean 6 standard deviation (SD). Differences in
responses among groups at various time points and between
groups and controls were analyzed using appropriate tests
Table 1. Demographic Characteristics and Immunological and Disease Profiles of Study Patients
Patient
(Sex, Age in y)
Duration of
Fever, d
Acute Illness
Severity
a
Anti-CHIKV
IgG Titer
b
Anti-CHIKV IgG3
Classiﬁcation
c
Clinical
Outcome
d
CHIKV 1 (M, 40) 3 Severe Low Early Complete recovery
CHIKV 2 (M, 23) 8 Severe High Early Complete recovery
CHIKV 3 (M, 62) 7 Severe High Early Lethargy, weakness
CHIKV 4 (M, 43) 5 Severe Low Early Complete recovery
CHIKV 5 (M, 29) 6 Severe Low Early Complete recovery
CHIKV 6 (M, 35) 7 Severe High Early Complete recovery
CHIKV 7 (M, 30) 4 Severe Low Early Complete recovery
CHIKV 8 (M, 35) 4 Severe High Early Complete recovery
CHIKV 9 (M, 26) 3 Severe High Early Complete recovery
CHIKV 10 (M, 28) 4 Severe Low Early Complete recovery
CHIKV 11 (M, 49) 2 Severe Low Early Complete recovery
CHIKV 12 (M, 50) 6 Severe Low Early Complete recovery
CHIKV 13 (M, 38) 3 Severe High Early Complete recovery
CHIKV 14 (M, 60) 3 Mild Low Early Complete recovery
CHIKV 15 (F, 62) 7 Severe High Early Complete recovery
CHIKV 16 (M, 45) 0 Mild High Early Complete recovery
CHIKV 17 (M, 34) 3 Mild High Late Complete recovery
CHIKV 18 (M, 29) 2 Severe Low Late Persistent arthralgia
CHIKV 19 (F, 67) 7 Mild High Late Complete recovery
CHIKV 20 (M, 24) 3 Mild Low Late Complete recovery
CHIKV 21 (M, 34) 0 Mild High Late Complete recovery
CHIKV 22 (M, 28) 7 Mild High Late Complete recovery
CHIKV 23 (M, 42) 2 Mild Low Late Complete recovery
CHIKV 24 (F, 40) 6 Mild Low Late Persistent arthralgia
CHIKV 25 (F, 31) 6 Mild Low Late Persistent arthralgia
CHIKV 26 (M, 46) 9 Mild High Late Complete recovery
CHIKV 27 (M, 26) 4 Mild Low Late Persistent arthralgia
CHIKV 28 (M, 28) 5 Severe Low Late Complete recovery
CHIKV 29 (M, 47) 8 Mild Low Late Complete recovery
CHIKV 30 (M, 39) 1 Mild High Late Complete recovery
Abbreviations: CHIKV, chikungunya virus; ELISA, enzyme-linked immunosorbent assay; F, female; IgG, immunoglobulin G; M, male.
a Severity was deﬁned as having a temperature .38.5C, pulse rate .100 beats per min, or platelet count ,100 3 10
9 cells/L.
b Anti-CHIKV IgG antibody titerwas determined byvirion-basedELISA from plasma samples collected at7–10 dpost–illness onset. Opticaldensityvalues . median
value of 0.46 were classiﬁed as high and the rest were deﬁned as low.
c Anti-CHIKV IgG3 isotype titer and response was determined by virion-based ELISA from plasma collected at 7–10 d post–illness onset. During this phase,
approximately half of the patient group already had a signiﬁcant increase of IgG3 antibodies, segregating this cohort into early and late IgG3 responders.
d Clinical outcome at chronic phase that is 2–3 months after post–illness onset.
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formed with GraphPad Prism 5.04 software.
RESULTS
Timing and Isotype Specificity of the Antibody Response
In order to characterize the immune response against CHIKV,
we prospectively followed up 30 patients who were admitted for
acute CHIKF during the CHIKF outbreak in Singapore between
August and September 2008 (Table 1)[ 9, 10]. CHIKV-speciﬁc
a n t i b o d yr e s p o n s e sw e r eq u a n t i ﬁ e di nt h ea c u t ep h a s es t a r t i n g
4 days after infection until the late chronic phase 2–3 months PIO
(Figure 1). As expected, IgG levels gradually increased during the
early convalescent phase at a median of 10 days PIO, whereas IgM
peaked after 4–6 weeks and declined to background levels (Figure
1A). Plasma from these patients was not only reactive to the
Chikungunya virion–based ELISA but also speciﬁcally detected
CHIKV antigens in CHIKV-infected cells by immunoﬂuorescence
staining (Figure 1B).
CHIKV-speciﬁc IgG antibodies were found to be almost
exclusively of the IgG3 isotype. The levels of virus-speciﬁc
IgG1, IgG2, and IgG4 titers did not increase during the
course of infection (Figure 1C) even when a high concen-
tration of plasma was used (Figure 1D). Although IgG3 was
the dominant isotype in all members of the cohort, a com-
parison of the individual titers during the early convales-
cence phase revealed striking differences within the patient
group. At a median of 10 days PIO, only approximately
half of the group already had a signiﬁcant increase of IgG3
(optical density .0.5), segregating this study cohort into
early and late IgG3 responders (Figure 1E, Table 1).
Figure 1. Antibody (Ab) profiles of chikungunya virus (CHIKV)–infected patients. A, Virus-specific immunoglobulin M (IgM) and immunoglobulin G (IgG)
antibody titers in plasma samples (n 5 30) at a dilution of 1:2000 were determined by enzyme-linked immunosorbent assay (ELISA) using purified CHIKV
virions. B, Detection of CHIKV by plasma from CHIKV-infected patients. HEK 293Tcells were infected with CHIKV (SGP11) at a multiplicity of infection of
10, fixed at 6 h postinfection, and stained with 2 representative patients' plasma at 2–3 months post–illness onset (PIO) using a dilution of 1:500. Healthy
plasma was used as a control. CHIKV antigen was detected by antihuman IgG antibody conjugated to Alexa Fluor 488 (green). 4#,6-diamidino-2-
phenylindole (DAPI) was used to stain the nucleus. Scale bar: 10 lm. C,Virus-specificIgG isotype titersin plasma samples. Immunoglobulin G1 (IgG1) (h),
immunoglobulin G2 (IgG2) (D), immunoglobulin G3 (IgG3) (d), or immunoglobulin G4 (IgG4) ()) Abs were determined as in (A) using specific secondary
antibodies. Each point represents the mean of 30 patients' samples from the cohort. D, Chikungunya virion–based ELISA was used to determine virus-
specific IgG isotype titers in plasma samples (median, 10 d PIO; n 5 30) at a dilution of 1:100. Anti-CHIKV IgG1, IgG2, IgG3, or IgG4 Abs were determined
using specific secondary Abs. Data are presented as mean 6 standard error of the mean (SEM) of 30 patients' samples and are representative of 2
independent experiments with similar results. E, Profile of IgG3 levels at different times PIO in early (n 5 16) and late IgG3 responders (n 5 14) according
to the pattern of IgG3 titer at median, 10 d PIO. Data are presented as mean 6 SEM. Data are representative of 2 independent experiments with similar
results. Statistical significance was measured using Mann–Whitney U test. **P ,.01. Abbreviation: OD, optical density.
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To determine if the antibodies also have protective capacity,
in vitro infections of HEK 293T cells with CHIKV were
carried out in the presence of plasma from patients or
healthy donors (Figure 2). The experiments revealed that
plasma samples collected at a median of 10 days PIO effec-
tively inhibited CHIKV infection (Figure 2A). Preincubation
of CHIKV with plasma samples induced a clear and dose-
dependent reduction in the detection of CHIKV antigens
(Figure 2A and 2B). In line with the observed differences in
IgG3 titer, plasma from early IgG3 responders showed
a higher neutralizing activity than plasma from the late IgG3
responders (Figure 2B) .T oc o n ﬁ r mt h ep r o t e c t i v er o l eo f
anti-CHIKV IgG3 antibodies, CHIKV-infected patient plasma
samples were depleted of antibodies against the puriﬁed
Chikungunya virion (Figure 3A). Removal of anti-CHIKV IgG3
antibodies led to a marked decrease in neutralization for both
early and late IgG3 responders (Figure 3B). In addition, the
partial removal of IgG3 from the plasma of CHIKV patients by
plate-bound anti-IgG3 reduced the IgG3 titer by 70%–80%
(Figure 3C) and led to a marked decrease in neutralization
for both early and late IgG3 responders (Figure 3D), conﬁrming
the importance of IgG3 antibodies in virus neutralization.
Association Studies
Because CHIKV IgG3 plays a key role in the control of
CHIKV infections, we examined viral load and disease pro-
gression in early and late IgG3 responders. First, we observed
a much higher viral load in the early IgG3 responders
compared with the late IgG3 responders (Figure 4A). This
was particularly evident on median day 4 PIO, suggesting
that the high IgG3 titers of early IgG3 responders are indeed
induced by a high viremia.
High viremia was also previously shown to correlate with
increased disease severity during the acute phase of infection
[17]. In line with this notion, we also observed that 90% of
early IgG3 responders developed severe disease during the
acute phase of the infection compared with ,10% of late
IgG3 responders (Figure 4B). In this cohort, disease severity
was previously shown to be associated with increased plasma
levels of 2 known endogenous pyrogens, interleukin 1b and
interleukin 6 (IL-6) [16, 17]. Interestingly, high levels of
IgG3 in early IgG3 responders also correlated with higher
IL-6 levels, especially during the initial phase of infection
(median, 4 days PIO) (Figure 4C). This ﬁnding may be ex-
plained by IL-6 being one of the major B-cell growth factors
[18] and a known inducer of IgG3 [19].
Figure 2. Neutralizing capacity of anti–chikungunya virus (CHIKV) immunoglobulin G3 (IgG3) antibodies. A, Visualization of CHIKV by
immunofluorescence in infected cultures after seroneutralization. Virus samples were preincubated with patients' plasma collected at median 10 d
post–illness onset (PIO) from early and late IgG3 groups before being added to the cells. Noninfected (mock) or virus samples preincubated with healthy
donor plasma were used as controls. Analysis was performed at 6 h postinfection. Images were captured with 603 magnification. Scale bar: 50 lm.
Representative microscopic images per treatment condition are illustrated. B, In vitro neutralizing activity against CHIKV from plasma samples of early
and late IgG3 responders. Plasma samples (median, 10 d PIO) were tested in triplicates at different dilutions. Healthy plasma was used as a control and
performed in the same conditions. Dilution at 1:100 is shown. Results are presented as mean 6 SD of percentage control infection. Data are
representative of 3 independent experiments. Statistical significance was measured using Mann–Whitney U test. *P ,.05. **P ,.01.
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indicated that early IgG3 responders exhibited a very efﬁcient
clearance of CHIKV. Although the average viral load on day 4
differed by . 3 logs, they reached similar low levels as the late
IgG3 responders after completing the acute phase of infection at
median 10 days pio (Figure 4D). Thus, the early increase of IgG3 is
apparently associated with an efﬁcient clearance of the virus.
Notably, although early IgG3 responders develop more severe
symptoms during the acute phase, they completely recovered
from the infection. None of them developed any persistent ar-
thralgia (Figure 4E). This, however, was not the case for late IgG3
responders. Despite having a low viremia, approximately 30% of
this group developed arthralgia during the later stage of the dis-
ease (Figure 4E). This suggests that a strong early IgG3 response
triggered by a high viral load is needed to fully protect against
chronic long-term effects of the CHIKV infection.
DISCUSSION
We have conducted the ﬁrst detailed longitudinal analysis of the
antibody response in a cohort of patients detected early during
a CHIKF outbreak. The study revealed that antibodies of the
IgG3 isotype dominate the humoral response against CHIKV.
This bias toward IgG3 production to virus infections has also
been previously reported in other pathogen infections [20, 21].
Long-term IgM production associated with persistence of
CHIKV [22] was not detected in this cohort.
The analysis of the cohort data revealed a clear correlation
between efﬁcient viral clearance and clinical protection against
persistent arthralgia and the early production of IgG3 anti-
bodies. A putative explanation may be that late IgG3 responders
established elevated levels of virus-speciﬁc IgG3 only at late
phase, a time when virus was no longer detectable in the blood.
In joint biopsies of patients with chronic arthralgia, CHIKV
was detected in cells such as macrophages [23]. This observation
has also been conﬁrmed by studies in a nonhuman primate
model [24]. It is plausible that the viruses in these cells are
nonreplicative, so that only few virions are released. These 2
studies have therefore proposed that viral reservoirs existed
in the afﬂicted joints, suggesting that CHIKV harboring at
these sites may be protected from the neutralization action
of the anti-CHIKV IgG3 antibodies. Late IgG3 responders
would therefore be more prone to persistent complications.
Figure 3. Roleofanti–chikungunyavirus (CHIKV)immunoglobulinG3 (IgG3)ininvitroneutralizingactivityagainstCHIKVfromplasmasamplesofearlyand
late IgG3 responders. A, Pooled plasma samples collected at median 10 d post–illness onset (PIO) (early IgG3, n 5 16; late IgG3, n 5 14) were added to
plates precoated with purified Chikungunya virion for depletion of anti-CHIKV antibodies. Depleted samples were subjected to anti-CHIKV IgG3 antibody
detection with virion-based enzyme-linked immunosorbent assay (ELISA). B, Depleted samples were subjected to in vitro neutralizing activity detection with
a seroneutralization assay. C, IgG3 antibodies from pooled plasma samples collected at a median of 10 d PIO (early IgG3, n 5 16; late IgG3, n 5 14) were
depleted as described in the ''Methods'' section and measured for anti-CHIKV IgG3 antibodies with virion-based ELISA. D, Depleted samples were subjected
toinvitroneutralizingdetectioninaseroneutralizationassay.Allsamplesassayedwereperformedat1:500dilution(n53).Plasmafromhealthydonorswas
used as negative controls. Data are presented as mean 6 SD. Data are representative of 3 independent experiments. Statistical significance was measured
using Mann–Whitney U test. *P ,.05. **P ,.01.
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efﬁcient viral clearance in vivo, an effect presumably medi-
ated by an inhibition of virus invasion and/or replication in
host cells. The neutralizing effect of IgG3 antibodies was also
evident in in vitro infection assays. Exposure of CHIKV to
IgG3-depleted patient plasma partly prevented its inhibitory
effect on the viral infection of HEK 293T cells. Although the
elevated titers of early CHIKV-speciﬁc antibodies are ap-
parently induced by high viremia, the isotype selection seems
to be linked to IL-6. The early increase of IgG3, apparently
induced by a high viremia, was clearly associated with a higher
production of the cytokine, which is known to be a major B-cell
growth factor [18]a n da ni n d u c e ro fI g G 3[ 19].
Due to the explosive nature of CHIKV outbreaks and the
unpreparedness of the healthcare system in countries where
they occurred, no longitudinal studies on anti-CHIKV im-
mune responses of this manner have been performed pre-
viously. It will be of interest to conﬁrm our ﬁndings with
cohorts from different parts of the world where CHIKV
outbreaks have been reported. The association of anti-CHIKV
IgG3 with clinical severity will allow for more cost-effective
patient management [25, 26], because a single determination
during acute phase would help predict severity.
Last, these studies, viewed in the broader context of im-
mune markers of protection against viral diseases, suggest
that the production of protective IgG3 antibodies correlate
with the virus titer. The paradoxical situation emerges in
which a high viral load during the acute phase is beneﬁcial
to establish full protection for the chronic phase. Low viremia,
in contrast, which causes less severe symptoms during the
initial phase, was proposed to be associated with persistent
arthralgia at later stages of the disease. Thus, the timely in-
duction of high titers of neutralizing IgG3 seems to be crucial
to prevent persistent complications arising from chronic viral
infections. Although this has important implications for
prevention and treatment of CHIKF, it remains to be seen if
Figure 4. Association of immunoglobulin G3 (IgG3) antibody responses with disease progression. A, Viral load in early and late IgG3 responders during the
acute phase of disease (median, 4 d post–illness onset [PIO]). Data are presented as mean 6 standard error of the mean. Statistical significance was
measuredusingMann–WhitneyUtest.***P,.001.Abbreviation:PFU,plaque-formingunits.B,DiseaseseverityinearlyandlateIgG3respondersduringthe
acute phase of disease. Severity was previously defined. Histogram shows the percentage of patients with mild (n 5 14) or acute severe clinical phenotypes
(n5 16).Statisticalsignificancewasmeasuredusing2-sidedFisherexacttestbetweenthenumberofpatients with severephenotype in2 respondergroups.
***P,.0001.C,Interleukin6levelsinearlyandlateIgG3respondersweredeterminedusingamultiplex-beadbasedassay.Horizontaldottedlinesrepresent
median values of healthy controls. Statistical significance was measured using Mann–Whitney U test. **P ,.01. D, Viral clearance from a median of 4 d to
a medianof10d PIO in early and late IgG3 responders. E, Persistent arthralgia in early andlateIgG3 responders duringthe chronic phase of disease(2–3 mo
PIO). Histogram shows the percentage of patients with full recovery or persistent arthralgia. Statistical significance was measured using 2-sided Fisher exact
test between the patients who have fully recovered and patients with persistent arthralgia in the 2 responder groups. *P 5 .04.
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and lasting symptoms.
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